Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytokinetics (CYTK) Cash from Operations: 2009-2024

Historic Cash from Operations for Cytokinetics (CYTK) over the last 16 years, with Dec 2024 value amounting to -$395.9 million.

  • Cytokinetics' Cash from Operations fell 5.91% to -$107.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$433.0 million, marking a year-over-year decrease of 7.08%. This contributed to the annual value of -$395.9 million for FY2024, which is 4.45% up from last year.
  • Latest data reveals that Cytokinetics reported Cash from Operations of -$395.9 million as of FY2024, which was up 4.45% from -$414.3 million recorded in FY2023.
  • Over the past 5 years, Cytokinetics' Cash from Operations peaked at $8.9 million during FY2020, and registered a low of -$414.3 million during FY2023.
  • In the last 3 years, Cytokinetics' Cash from Operations had a median value of -$395.9 million in 2024 and averaged -$369.9 million.
  • As far as peak fluctuations go, Cytokinetics' Cash from Operations spiked by 109.84% in 2020, and later crashed by 1,693.67% in 2021.
  • Yearly analysis of 5 years shows Cytokinetics' Cash from Operations stood at $8.9 million in 2020, then slumped by 1,693.67% to -$142.5 million in 2021, then tumbled by 110.15% to -$299.5 million in 2022, then tumbled by 38.33% to -$414.3 million in 2023, then climbed by 4.45% to -$395.9 million in 2024.